Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Tiziana Life Sciences’ research team has discovered that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company anticipates that Bcl-3 will progress to clinical trials in 2016.
Type
Public
HQ
London, GB
Founded
2013
Size (employees)
5 (est)+25%
Tiziana Life Sciences was founded in 2013 and is headquartered in London, GB

Tiziana Life Sciences Office Locations

Tiziana Life Sciences has an office in London
London, GB (HQ)
18 South St

Tiziana Life Sciences Financials and Metrics

Tiziana Life Sciences Financials

Tiziana Life Sciences's revenue was reported to be (£6.3 m) in FY, 2015 which is a 692% increase from the previous period.
GBP

Net income (FY, 2016)

(7.2 m)

EBITDA (FY, 2016)

(7.3 m)

EBIT (FY, 2016)

(7.3 m)

Market capitalization (20-Oct-2017)

141 m

Closing share price (20-Oct-2017)

1.5

Cash (31-Dec-2016)

4.7 m
Tiziana Life Sciences's current market capitalization is £141 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2014FY, 2015FY, 2016

Revenue

311 k91.7 k56.1 k187.7 k(82 k)(195 k)(794 k)(6.3 m)

Revenue growth, %

692%

Cost of goods sold

108 k20.4 k11 k69.9 k

Gross profit

203 k71.3 k45 k117.9 k
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

588 k25.2 k30.4 k69.4 k33 k4 k2.3 m8.9 m4.7 m

Accounts Receivable

56 k16 k23.8 k38.4 k

Inventories

7 k28.6 k38.2 k10.5 k

Current Assets

954 k221.4 k165.2 k182.7 k462 k27 k2.5 m9.3 m5 m
    GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2014FY, 2015FY, 2016

    Net Income

    (2.4 m)(1.4 m)(729.9 k)(1.1 m)(778 k)(653 k)(3.3 m)(8.6 m)(7.2 m)

    Cash From Operating Activities

    2.2 m(914.4 k)(547.6 k)(403.8 k)(853 k)(210 k)(2.2 m)(5.5 m)(5.1 m)

    Cash From Financing Activities

    2.3 m451.2 k598.7 k554.7 k1.5 m67 k4.4 m12.1 m1.2 m

    Net Change in Cash

    102 k(563.9 k)8.3 k48.6 k33 k(29 k)2.3 m6.6 m(4.2 m)
      Y, 2016

      Financial Leverage

      1.5 x
      Show all financial metrics

      Tiziana Life Sciences Market Value History

      Traffic Overview of Tiziana Life Sciences

      Tiziana Life Sciences Online and Social Media Presence

      Tiziana Life Sciences Company Life and Culture

      You may also be interested in